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Standfirst | [Au: Please provide a brief (50-word) mini-abstract summarizing the 
main messages of this article]  
 
[Au: As an alternative, perhaps you could adapt the following suggested standfirst?]  
Glioblastoma remains essentially incurable, and new therapeutic approaches are urgently 
needed. Now, the findings of three serial tissue-based studies suggest that immune-
checkpoint inhibition can modify the glioblastoma microenvironment. Following these 
encouraging observations, the results of two phase III trials of immune-checkpoint 
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inhibition in newly diagnosed glioblastoma with larger cohorts of patients are eagerly 
anticipated.  
 
Gliomas are intrinsic brain tumours thought to arise from neuroglial progenitor cells that 
are highly infiltrative, often angiogenic and essentially incurable. Glioblastoma, the most 
common variant, is defined as a glial tumour with certain histological characteristics 
including necrosis and vascular proliferation. Moreover, there are typical molecular 
features found in subsets of glioblastomas, such as gain of chromosome 7 and loss of 
chromosome 10, EGFR amplifications, and telomerase reverse transcriptase promoter 
mutations. The vast majority of glioblastomas harbour genetic alterations in the PI3K, 
retinoblastoma and/or p53 signalling pathways.1  
 
The standard of care for patients with newly diagnosed glioblastoma consists of 
neurosurgical resection, as safely feasible, followed by involved field radiotherapy with 
concomitant and maintenance temozolomide chemotherapy. At recurrence, second 
surgery and re-irradiation are both options for some patients, but most patients will 
receive second-line systemic chemotherapy with either alkylating agents, such as 
lomustine, or bevacizumab.2 Median survival durations of patients receiving these 
treatments remain in the range of 1 year according to registry-based epidemiological 
studies. Numerous attempts to improve these outcomes by adding novel systemic agents 
to the standard of care in the first-line setting, including a phase III trial exploring the 
efficacy of a vaccine targeting EGFR variant III, exhibiting loss of exons 2–7, have failed 
to improve overall survival.3 Furthermore, the first phase III trial involving immune-
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checkpoint inhibitors in neuro-oncology, CheckMate 143 (NCT02017717), in which the 
efficacy of nivolumab was compared with that of bevacizumab in patients with 
glioblastoma at first relapse, did not demonstrate superiority of nivolumab in the overall 
patient population.4 The results of this trial are of continued interest because 
interpretation of the outcomes is dependent on whether bevacizumab alone is considered 
an active agent in this setting – this has never been formally tested. Furthermore, ongoing 
subgroup analyses of data from this trial might aid in identifying patients who are more 
likely, or less likely, to derive benefit from either nivolumab or bevacizumab. However, 
the recognition of glioblastoma as the paradigmatic lymphocyte-depleted cancer5 has 
further dampened the great expectations that immunotherapy might provide a therapeutic 
breakthrough in this disease. To date, demonstrations of clinical benefit from immune-
checkpoint inhibition in patients with glioblastoma have been limited to individual 
patients whose tumours have excessively high mutational burdens owing to mismatch 
repair deficiencies. 
 
This scenario provided the framework for three recent studies published in Nature 
Medicine, in which investigators attempted to identify predictors of benefit from 
immune-checkpoint inhibition and whether these agents have any measurable level of 
biological activity in patients with glioblastomas.6-8  
 
Zhao and colleagues6 attempted to distinguish responders to immune-checkpoint 
inhibition from nonresponders. Following genomic and transcriptomic analyses, these 
investigators proposed that phosphatase and tensin homolog (PTEN) mutations are linked 
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with immunosuppressive gene-expression signatures and resistance to immune-
checkpoint inhibition, whereas tumours from responders were found to harbour mitogen-
activated protein kinase (MAPK) pathway alterations. 
 
Schalper and colleagues7 adopted a pharmacodynamic approach, often referred to as a 
phase 0 study, in which they administered a single presurgical (at 2 weeks ± 3 days prior 
to surgery) dose of nivolumab to 30 patients, the majority of whom (n = 27) had recurrent 
disease. The evolution of the tumour microenvironment of these patients was then 
compared to that of a reference cohort that was not exposed to immune-checkpoint 
inhibitors. The authors reported that nivolumab induced increased expression of several 
chemokine transcripts, promoted immune-cell infiltration and augmented T cell receptor 
clonal diversity in the tumour-infiltrating T cell compartment. 
 
Data from these two studies6,7 seem to demonstrate that the glioblastoma TME is indeed 
not completely refractory to the immunomodulatory effects of immune-checkpoint 
inhibition. However, one might still argue that clinical benefit from immune-checkpoint 
inhibition, as defined by Zhao et al.6, remains controversial and that the historical control 
group presented by Schalper et al.7 leaves doubts as to whether or not the effects on the 
microenvironment are specifically mediated by nivolumab; moreover, these studies, by 
design, do not provide evidence of clinical benefit. These various shortcomings are 
largely overcome by the data reported by Cloughesy et al.8 who conducted a small, 
randomized phase 0/2 study in which patients with recurrent glioblastoma who were 
considered candidates for second surgery received pembrolizumab. Patients were 
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randomly assigned to receive either adjuvant pembrolizumab alone or a single presurgical 
dose of pembrolizumab (14 ± 5 days prior to surgery) followed by adjuvant 
pembrolizumab. When compared with the adjuvant only group, presurgical 
pembrolizumab resulted in the induction of a T cell-related and IFNγ-related gene 
expression signature with clonal T cell expansion, demonstrating that the glioblastoma 
TME can potentially be modified even by a single dose of pembrolizumab. 
Unexpectedly, patients who had been randomly assigned to receive a single presurgical 
dose of pembrolizumab also had prolonged overall survival durations (13.7 months 
versus 7.5 months, HR 0.43, 95% CI 0.20–0.90; P = 0.03). Imbalances in patient 
characteristics, if they had any effect, would have favoured the adjuvant only group 
because 69% of patients in this group had O6-methylguanine DNA methyltransferase 
(MGMT) promoter methylation as opposed to 38% in the presurgical group. Admittedly, 
this was a small study (n = 32) in which overall survival was a secondary or exploratory 
end point. Yet, this observation of significantly longer overall survival after a single 
presurgical dose of pembrolizumab encourages speculation regarding whether the 
iatrogenic trauma of surgery facilitates a durable immune response once the 
immunosuppressive properties of glioblastoma are counterbalanced by immune-
checkpoint inhibition. Future studies with similar designs, potentially even involving 
combinations of immune-checkpoint inhibitors, are likely to follow.  
 
Meanwhile, two phase III randomized prospective trials exploring the activity, safety and 
tolerability of nivolumab in patients with newly diagnosed glioblastoma have completed 
patient enrollment, although data are yet to be analysed. CheckMate 498 (NCT02617589) 
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took advantage of the emerging concept that temozolomide can be omitted from the first-
line treatment of patients with MGMT promoter-unmethylated glioblastoma owing to 
only marginal benefits of this approach in this patient population.9 Accordingly, 
CheckMate 498 is designed to compare the efficacy of radiotherapy plus nivolumab with 
that of radiotherapy plus temozolomide as the current standard of care in these patients. 
The companion trial, CheckMate 548 (NCT02667587), is a placebo-controlled trial 
designed to explore the efficacy of the addition of nivolumab to standard-of-care 
chemoradiotherapy in patients with MGMT-promoter-methylated glioblastoma. A 
concern remains that the combination of a cytotoxic agent with an immune-checkpoint 
inhibitor might abrogate any activation of the T cell compartment and could thus inhibit 
any relevant anti-tumour activity. However, data from animal models indicate that part of 
the antitumour activity of temozolomide might indeed be immune-mediated10 and chronic 
exposure to temozolomide might also deplete the regulatory T cell pool. These 
considerations, plus the assumption, as yet unproven, that prolonged treatment with 
temozolomide steadily increases the tumour mutational burden of patients with newly 
diagnosed MGMT-methylated glioblastoma, supports the notion that CheckMate 548 
may provide the first positive phase III data from a trial involving immunotherapy in 
patients with brain tumours. The community will know soon. 
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